Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Current Leases (2020 - 2025)

Altimmune (ALT) has disclosed Current Leases for 6 consecutive years, with $247000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Current Leases fell 21.09% to $247000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $247000.0, a 21.09% decrease, with the full-year FY2024 number at $279000.0, down 43.75% from a year prior.
  • Current Leases was $247000.0 for Q3 2025 at Altimmune, up from $239000.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $508000.0 in Q1 2024 to a low of $239000.0 in Q2 2025.
  • A 5-year average of $390687.5 and a median of $426000.0 in 2022 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: increased 15.22% in 2021, then crashed 51.77% in 2025.
  • Altimmune's Current Leases stood at $411000.0 in 2021, then rose by 9.98% to $452000.0 in 2022, then rose by 9.73% to $496000.0 in 2023, then plummeted by 43.75% to $279000.0 in 2024, then decreased by 11.47% to $247000.0 in 2025.
  • Per Business Quant, the three most recent readings for ALT's Current Leases are $247000.0 (Q3 2025), $239000.0 (Q2 2025), and $245000.0 (Q1 2025).